CRA experts advised counsel and presented before the FTC on transactions involving Novartis’ acquisition of cancer drugs from GlaxoSmithKline, GSK’s joint venture with Novartis on consumer health, and Novartis’s sale of Novartis Animal Health to Eli Lilly & Co. The deals ultimately went forward with certain divestitures.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...